Late Preterm Antenatal Corticosteroids in Pregestational and Gestational Diabetic Pregnancies

Lylach Haizler-Cohen1, Maria C Alzamora1, Nicole R Legro1

  • 1Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, MedStar Washington Hospital Center, Washington, District of Columbia.

Insights

Late preterm antenatal corticosteroids (ACS) in diabetic pregnancies did not increase neonatal hypoglycemia or improve overall respiratory issues. However, a complete ACS course did reduce the need for respiratory support in some cases.

Area of Science:

  • Maternal-Fetal Medicine
  • Neonatology
  • Endocrinology

Background:

  • Late preterm birth presents risks for neonates, particularly those exposed to maternal diabetes.
  • Antenatal corticosteroids (ACS) are used to mature fetal lungs but their role in diabetic pregnancies during the late preterm period is debated.
  • Neonatal hypoglycemia and respiratory complications are significant concerns in infants born to mothers with pregestational diabetes mellitus (PGDM) and gestational diabetes mellitus (GDM).

Purpose of the Study:

  • To evaluate the association between late preterm antenatal corticosteroids (ACS) administration and neonatal hypoglycemia.
  • To assess the impact of late preterm ACS on respiratory complications in neonates born to mothers with PGDM and GDM.
  • To explore the influence of diabetes type and glycemic control on these associations.

Main Methods:

  • Multi-center retrospective cohort study (2016-2022) including pregnant individuals with PGDM or GDM in the late preterm period.
  • Primary outcome: neonatal hypoglycemia. Secondary outcomes: composite respiratory morbidity, NICU admission, length of NICU stay, neonatal death.
  • Multivariable regression models adjusted for admission indication, gestational age, and birth weight; stratified analyses by diabetes type, ACS completion, and glycemic control for PGDM.

Main Results:

  • No significant difference in neonatal hypoglycemia or composite respiratory morbidity between ACS and non-ACS groups in either PGDM or GDM subgroups.
  • A complete course of late preterm ACS was associated with reduced supplemental oxygen use, mechanical ventilation, and respiratory distress syndrome.
  • In PGDM pregnancies, neonatal outcomes did not differ between ACS and non-ACS groups, irrespective of glycemic control.

Conclusions:

  • Late preterm ACS administration in diabetic pregnancies is not associated with increased neonatal hypoglycemia or improved composite respiratory morbidity.
  • A complete course of late preterm ACS may offer respiratory benefits, specifically reducing the need for respiratory support.
  • Maternal glycemic control does not appear to modify neonatal outcomes related to late preterm ACS use in diabetic pregnancies.

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.3K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
412
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
278
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.3K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
642